m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG02639)
Name
Double Oxidized Cysteine
Status
Investigative
Structure
Formula
C3H6NO4S-
InChI
1S/C3H7NO4S/c4-2(3(5)6)1-9(7)8/h2H,1,4H2,(H,5,6)(H,7,8)/p-1/t2-/m0/s1
InChIKey
ADVPTQAUNPRNPO-REOHCLBHSA-M
PubChem CID
6398956
TTD Drug ID
D0H1GU
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Cyclin-dependent kinase 2 (CDK2)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for Double Oxidized Cysteine. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Double Oxidized Cysteine through regulating the expression of Cyclin-dependent kinase 2 (CDK2). [1], [2]
YTH domain-containing family protein 1 (YTHDF1)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for Double Oxidized Cysteine. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Double Oxidized Cysteine through regulating the expression of Cyclin-dependent kinase 2 (CDK2). [2], [3]
YTH domain-containing family protein 2 (YTHDF2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for Double Oxidized Cysteine. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Double Oxidized Cysteine through regulating the expression of Cyclin-dependent kinase 2 (CDK2). [1], [2]
M-phase inducer phosphatase 2 (MPIP2)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary M-phase inducer phosphatase 2 (MPIP2) is a therapeutic target for Double Oxidized Cysteine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Double Oxidized Cysteine through regulating the expression of M-phase inducer phosphatase 2 (MPIP2). [4], [5]
References
Ref 1 FTO regulates adipogenesis by controlling cell cycle progression via m(6)A-YTHDF2 dependent mechanism. Biochim Biophys Acta Mol Cell Biol Lipids. 2018 Oct;1863(10):1323-1330. doi: 10.1016/j.bbalip.2018.08.008. Epub 2018 Aug 13.
Ref 2 Docking-based development of purine-like inhibitors of cyclin-dependent kinase-2. J Med Chem. 2000 Jun 29;43(13):2506-13. doi: 10.1021/jm990506w.
Ref 3 YTHDF1 links hypoxia adaptation and non-small cell lung cancer progression. Nat Commun. 2019 Oct 25;10(1):4892. doi: 10.1038/s41467-019-12801-6.
Ref 4 METTL3 modulates m6A modification of CDC25B and promotes head and neck squamous cell carcinoma malignant progression. Exp Hematol Oncol. 2022 Mar 14;11(1):14. doi: 10.1186/s40164-022-00256-3.
Ref 5 DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. doi: 10.1093/nar/gkq1126. Epub 2010 Nov 8.